Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Andreas H. Wille is active.

Publication


Featured researches published by Andreas H. Wille.


European Urology | 2010

Positive Surgical Margin Appears to Have Negligible Impact on Survival of Renal Cell Carcinomas Treated by Nephron-Sparing Surgery

K. Bensalah; Allan J. Pantuck; Nathalie Rioux-Leclercq; Rodolphe Thuret; Francesco Montorsi; Pierre I. Karakiewicz; Nicolas Mottet; Laurent Zini; Roberto Bertini; Laurent Salomon; A. Villers; Michel Soulie; L. Bellec; P. Rischmann; Alexandre de la Taille; R. Avakian; Maxime Crepel; Jean Marie Ferriere; Jean Christophe Bernhard; Thierry Dujardin; Frédéric Pouliot; J. Rigaud; Christian Pfister; Baptiste Albouy; L. Guy; Steven Joniau; Hendrik Van Poppel; Thierry Lebret; T. Culty; Fabien Saint

BACKGROUND The occurrence of positive surgical margins (PSMs) after partial nephrectomy (PN) is rare, and little is known about their natural history. OBJECTIVE To identify predictive factors of cancer recurrence and related death in patients having a PSM following PN. DESIGN, SETTING, AND PARTICIPANTS Some 111 patients with a PSM were identified from a multicentre retrospective survey and were compared with 664 negative surgical margin (NSM) patients. A second cohort of NSM patients was created by matching NSM to PSM for indication, tumour size, and tumour grade. MEASUREMENTS PSM and NSM patients were compared using student t tests and chi-square tests on independent samples. A Cox proportional hazards regression model was used to test the independent effects of clinical and pathologic variables on survival. RESULTS AND LIMITATIONS Mean age at diagnosis was 61+/-12.5 yr. Mean tumour size was 3.5+/-2 cm. Imperative indications accounted for 39% (43 of 111) of the cases. Some 18 patients (16%) underwent a second surgery (partial or total nephrectomy). With a mean follow-up of 37 mo, 11 patients (10%) had recurrences and 12 patients (11%) died, including 6 patients (5.4%) who died of cancer progression. Some 91% (10 of 11) of the patients who had recurrences and 83% of the patients (10 of 12) who died belonged to the group with imperative surgical indications. Rates of recurrence-free survival, of cancer-specific survival, and of overall survival were the same among NSM patients and PSM patients. The multivariable Cox model showed that the two variables that could predict recurrence were the indication (p=0.017) and tumour location (p=0.02). No other variable, including PSM status, had any effect on recurrence. None of the studied parameters had any effect on the rate of cancer-specific survival. CONCLUSIONS PSM status occurs more frequently in cases in which surgery is imperative and is associated with an increased risk of recurrence, but PSM status does not appear to influence cancer-specific survival. Additional follow-up is needed.


The Journal of Urology | 1993

Excretion of Urinary Enzymes After Extracorporeal Shock Wave Lithotripsy: A Critical Reevaluation

Klaus Jung; Peter Kirschner; Andreas H. Wille; Gerald Brien

The excretion of the urinary enzymes alanine aminopeptidase, alkaline phosphatase, gamma-glutamyl-transferase and N-acetyl-beta-D-glucosaminidase, and the 99mtechnetium-diethylenetriaminepentaacetic acid isotope clearance were studied in 35 patients treated with extracorporeal shock wave lithotripsy (ESWL*). Enzyme measurements were made before and consecutively on days 1, 2 and 5, and at 3 months after treatment. A control group investigated at the same intervals was included. Posttreatment enzyme values were not significantly different from those before treatment except for alkaline phosphatase on day 1 after ESWL. Some individuals had short-term increases of enzymuria that were greater than biological variations in the control group. The transient changes of enzymuria after ESWL had no predictive value for kidney function, since no decreased renal function was observed in individual patients with high enzyme excretions after ESWL.


Urologe A | 2002

Die radikale Prostatektomie beim klinisch lokalisierten Prostatakarzinom Pro laparoskopischer Zugangsweg

Ingolf Türk; Serdar Deger; Björn Winkelmann; P. Brettschneider; Jan Roigas; Andreas H. Wille; S.A. Loening

ZusammenfassungDie logische Folge der konsquenten Weiterentwicklung der Laparoskopie im letzten Jahrzehnt war die Etablierung der laparoskopischen radikalen Prostatektomie (LRP). Basierend auf umfangreichen eigenen Erfahrungen werden die Vorteile dieser minimal-invasiven Methode neben noch bestehenden Problemen beschrieben.Die gute intraoperative Übersicht mit hervorragender Detailerkennung (Vergrößerungseffekt) ermöglicht ein subtiles Operieren mit geringerer Traumatisierung wichtiger neuromuskulärer Strukturen. Extrem kurze Katheterverweilzeiten und sehr gute funktionelle Ergebnisse hinsichtlich Kontinenz und Potenz sind die Folge. Für einen derart komplizierten und komplexen Eingriff wie die LRP ist eine Komplikationsrate von durchschnittlich 12% akzeptabel und verdeutlicht, dass die LRP das Stadium der experimentellen Chirurgie verlassen hat.Die Kosten der LRP sind betriebswirtschaftlich gesehen zunächst höher, verglichen mit dem offen chirurgischen Vorgehen, werden aber durch die geringere Morbididtät, die geringere Krankenhausverweildauer und kürzere Rekonvaleszens volkswirtschaftlich gesehen ausgeglichen. Die künftig zu erwartenden Fortschritte in der technischen Entwicklung der Laparoskopie werden die Qualität, die Präzision und die Sicherheit der LRP weiter erhöhen und damit zu ihrer Etablierung als chirurgische Methode der Wahl beitragen.AbstractSystematic development of laparoscopy during the last decade has led to establishing laparoscopic radical prostatectomy (LRP) as a surgical procedure. On the basis of extensive experience at our center, the advantages of the minimally invasive method are described as well as the problems still in existence. Reduced trauma caused by laparoscopic access in combination with clearly reduced blood loss has resulted in less morbidity after laparoscopic procedures. This is reflected in a shorter postoperative stay in hospital and faster convalescenceLRP as an ambitious and complex procedure has an average complication rate of 12%, which shows that the method has surpassed the stage of experimental surgery. By direct comparison, the costs of LRP are higher than for the open surgical procedure, but on the whole this is economically balanced by the lower morbidity, shorter hospital stay, and faster convalescence.The progress in technology to be expected in the field of laparoscopy will further increase quality, precision, and safety of LRP and thus contribute to the establishment of laparoscopic radical prostatectomy as a surgical method of choice.


Cancer Biotherapy and Radiopharmaceuticals | 2003

Effects of 13-cis-retinoic acid on chemoimmunotherapy of metastatic renal cell carcinoma: Results of a retrospective analysis

J. Roigas; Serdar Deger; Kasra Taymoorian; Andreas H. Wille; Manfred Johannsen; Ingolf Türk; Dietmar Schnorr; Stefan A. Loening

Chemoimmunotherapy (CIT) with interleukin-2, interferon-alpha2a, and 5-fluorouracil is an accepted treatment option of metastatic renal cell carcinoma (mRCC). Because of the enhancement of the antiproliferative effects of interferon-alpha2a, 13-cis-retinoic acid (13-CRA) might be of potential usefulness for immunotherapy. We have investigated the effect of 13-CRA in patients treated with chemoimmunotherapy. Seventy-two patients with mRCC and a Karnofsky performance index > or = 80% were retrospectively analyzed. Thirty-six patients received chemoimmunotherapy and 36 other patients were treated similarly but with addition of daily 60 mg 13-CRA. Response was assessed according to the UICC criteria. Survival was calculated by Kaplan Meier estimation and compared with the log-rank test. In the CIT group objective remissions occurred in 34.3% (95% CI 19.1-52.2) and stabilizations in 42.9% (median follow-up 16 months). In the CIT plus 13-CRA group, objective remissions were seen in 26.4% (95% CI 12.9-44.4) and stabilizations in 50% (median follow-up 17 months). One- and three-year survival rates were 76% and 32% in the CIT group and 82% and 37% in the CIT plus 13-CRA group. The combination of CIT and 13-CRA did not significantly differ in objective remissions and estimated survival compared with CIT. Our retrospective data suggest that 13-CRA does not enhance the therapeutic efficacy of CIT in mRCC patients with a good performance status.


European Urology | 2004

Laparoscopic Radical Nephrectomy: Techniques, Results and Oncological Outcome in 125 Consecutive Cases

Andreas H. Wille; Jan Roigas; Serdar Deger; M. Tüllmann; Türk I; Stefan A. Loening


European Urology | 2006

Laparoscopic Partial Nephrectomy in Renal Cell Cancer – Results and Reproducibility by Different Surgeons in a High Volume Laparoscopic Center

Andreas H. Wille; M. Tüllmann; Jan Roigas; Stefan A. Loening; Serdar Deger


European Urology | 2004

Thermoradiotherapy Using Interstitial Self-Regulating Thermoseeds: An Intermediate Analysis of a Phase II Trial

Serdar Deger; Kasra Taymoorian; Dirk Boehmer; Tanja Schink; Jan Roigas; Andreas H. Wille; V. Budach; Klaus-Dieter Wernecke; Stefan A. Loening


The Journal of Urology | 2009

CHYLOUS ASCITES AFTER LAPAROSCOPIC RPLND - INCIDENCE AND MANAGEMENT

Andreas H. Wille; Andreas Römer; Jan Roigas; Kurt Miller; Serdar Deger


European Urology Supplements | 2007

Laparoscopic Partial Nephrectomy in Renal Cell Cancer—Indications, Technique, and Outcome in 80 Patients

Andreas H. Wille; Serdar Deger; M. Tüllmann; Ann Lau; M. Johannsen; Michael Lein; Stefan A. Loening; Jan Roigas


European Urology Supplements | 2008

ARE THERE DETERMINANT PREDICTIVE FACTORS FOR OPTIMISING THE MANAGEMENT OF PATIENTS WITH POSITIVE MARGINS FOLLOWING NEPHRON-SPARING SURGERY?

J.J. Patard; K. Bensalah; A.J. Pantuck; F. Montorsi; Pierre I. Karakiewicz; Nicolas Mottet; L. Zini; Roberto Bertini; L. Salomon; C.C. Abbou; A. Villers; M. Soulié; L. Bellec; P. Rischmann; A. De La Taille; R. Avakian; Maxime Crepel; G. Verhoest; Jean-Marie Ferriere; Hervé Wallerand; Jean-Christophe Bernhard; Thierry Dujardin; F. Guille; Frédéric Pouliot; J. Rigaud; Christian Pfister; Baptiste Albouy; L. Guy; Steven Joniau; Thierry Lebret

Collaboration


Dive into the Andreas H. Wille's collaboration.

Top Co-Authors

Avatar

Jan Roigas

Humboldt University of Berlin

View shared research outputs
Top Co-Authors

Avatar

Serdar Deger

Humboldt University of Berlin

View shared research outputs
Top Co-Authors

Avatar

Stefan A. Loening

United States Department of Veterans Affairs

View shared research outputs
Top Co-Authors

Avatar

Stefan A. Loening

United States Department of Veterans Affairs

View shared research outputs
Top Co-Authors

Avatar

Dietmar Schnorr

Humboldt University of Berlin

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

M. Tüllmann

Humboldt University of Berlin

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge